Triterpenoid antifungals for the treatment or prevention of Pneumocystis spp. pneumonia
Inventors
Angulo Gonzalez, David A. • Barat, Stephen Andrew
Assignees
Interested in licensing this patent?
MTEC can help explore whether this patent might be available for licensing for your application.
Abstract
Eufumafungin derivative triterpenoid antifungal compounds are used to treat and/or prevent Pneumocystis pneumonia (PCP) due to their unexpected efficacy against Pneumocystis spp. including their ability to reduce the lung burden of cyst and trophic forms of this fungi. The enfumafungin derivative triterpenoids (or pharmaceutically acceptable salts or hydrates thereof) are inhibitors of (1,3)-β-D-glucan synthesis and are useful in the treatment and/or prevention of PCP since they demonstrate potent activity against Pneumocystis spp. in in vivo models, exhibit adequate tissue penetration into lungs, and are well tolerated.
Core Innovation
The disclosed invention uses an enfumafungin-derived triterpenoid glucan-synthase inhibitor, particularly ibrexafungerp, to treat or prevent Pneumocystis pneumonia. The claims describe administering a Formula (II) or Formula (IIa) compound, or a pharmaceutically acceptable salt or hydrate, to a subject; certain claims specify treatment of Pneumocystis jirovecii pneumonia in a human.
The provided partial content identifies Pneumocystis pneumonia as the condition addressed and reports reduced cyst and trophic burdens in murine prophylaxis and treatment models. It does not include the patent's background section or describe a specific problem with existing treatments, so the stated problem being solved cannot be further characterized from this content.
Claims Coverage
The relevant claims include three independent claims covering methods of treating Pneumocystis pneumonia with Formula (II), Formula (IIa), or a pharmaceutically acceptable salt of Formula (IIa).
Treatment with formula (II)
The claim covers treating Pneumocystis pneumonia in a subject by administering the specified Formula (II) compound or a pharmaceutically acceptable salt or hydrate thereof. Dependent claims specify Pneumocystis jirovecii, reduction of cyst and trophic burdens, and human subjects.
Treatment of human Pneumocystis jirovecii pneumonia with formula (IIa)
The claim covers treating Pneumocystis jirovecii pneumonia in a human by administering the specified Formula (IIa) compound or a pharmaceutically acceptable salt or hydrate thereof. Dependent claims further specify salt forms and treatment outcomes; [procedural detail omitted for safety].
Treatment with a pharmaceutically acceptable salt of formula (IIa)
The claim covers treating Pneumocystis jirovecii pneumonia in a human by administering a pharmaceutically acceptable salt of the specified Formula (IIa) compound. A dependent claim specifies the citrate salt.
Together, the independent claims cover treatment of Pneumocystis pneumonia using the specified Formula (II) compound, Formula (IIa) compound, or a pharmaceutically acceptable salt of Formula (IIa). The dependent claims add organism, subject, salt-form, and treatment-outcome limitations.
Stated Advantages
The compound is reported to reduce both cyst and trophic burdens in murine prophylaxis and treatment models.
The reported activity is comparable to TMP-SMX for several outcomes.
The compound is reported to achieve high lung exposure relative to plasma and to be well tolerated.
Documented Applications
Treatment or prevention of Pneumocystis pneumonia, including Pneumocystis jirovecii pneumonia.
The document reports prophylaxis and treatment efficacy in murine models.
Interested in licensing this patent?